プレマーケット: 3.55 0.02 +0.57%

Tharimmune Inc (THAR)

Tharimmune Inc (THAR) 最新ニュース

Tharimmune Inc (THAR)

Tharimmune Inc (THAR) 最新ニュース

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com Australia

Tharimmune to sell 659,545 shares at $3.16 in private placement - TipRanks.com - TipRanks

Tharimmune to sell 659,545 shares at $3.16 in private placement - TipRanks.com - TipRanks

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com Australia

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com UK

Tharimmune Announces $2.08 Million Private Placement | THAR Stock News - StockTitan

Tharimmune raises $2.08 million in private placement By Investing.com - Investing.com

Tharimmune announces Type C meeting with FDA for Phase 2 TH104 program - TipRanks.com - TipRanks

THAR: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle

FDA nods to Tharimmune's Phase 2 itch relief trial plan By Investing.com - Investing.com

FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com India

FDA nods to Tharimmune's Phase 2 itch relief trial plan - Investing.com South Africa

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for ... - StockTitan

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for ... - StockTitan

Tharimmune announces Type C meeting with FDA for Phase 2 TH104 program - TipRanks.com - TipRanks

Tharimmune announces results of Phase 1 trial of TH104 - TipRanks.com - TipRanks

Tharimmune (THAR) Reports Positive Results of Phase 1 Trial in Healthy Subjects with TH104 - StreetInsider.com

Why Tharimmune (THAR) Shares Are Getting Hammered - MSN

Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com Canada

Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com

Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com Canada

Why Tharimmune (THAR) Shares Are Getting Hammered - Tharimmune (NASDAQ:THAR) - Benzinga

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for ... - Yahoo Finance

Tharimmune reports promising Phase 1 results for TH104 By Investing.com - Investing.com UK

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Drops By 83.2% - MarketBeat

Investor's Toolkit: Key Ratios for Assessing Tharimmune Inc (THAR)'s Performance – DWinneX - The Dwinnex

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Drops By 83.2% - MarketBeat

Why Is Tharimmune (THAR) Stock Moving Today? - MSN

Prepare Yourself for Liftoff: Tharimmune Inc (THAR) – Sete News - SETE News

Why Is Tharimmune (THAR) Stock Moving Today? - InvestorPlace

Why Is Tharimmune (THAR) Stock Moving Today? - InvestorPlace

Tharimmune Stock Set to Reverse Split on Tuesday, May 28th (NASDAQ:THAR) - Defense World

Tharimmune announces 1-for-15 reverse stock split - TipRanks.com - TipRanks

Upward Trajectory: Tharimmune Inc (THAR) Posts a Slidee, Closing at 0.33 – DWinneX - The Dwinnex

Tharimmune Inc (THAR) Stock: A Year of Decreases and Increases - The InvestChronicle

Tharimmune announces 1-for-15 reverse stock split By Investing.com - Investing.com

Tharimmune announces 1-for-15 reverse stock split By Investing.com - Investing.com UK

Why Tharimmune (THAR) Shares Are Moving - Tharimmune (NASDAQ:THAR) - Benzinga

Tharimmune (NASDAQ:THAR) Stock Price Up 3.9% - Defense World

Why Tharimmune (THAR) Shares Are Moving - Tharimmune (NASDAQ:THAR) - Benzinga

THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 - MSN

THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 - InvestorPlace

Tharimmune enters option agreement with Washington University - TipRanks.com - TipRanks

Tharimmune Announces Option for Novel HER2/HER3 Cancer Therapies - Contract Pharma

Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now - GlobeNewswire

Tharimmune's buccal film liver drug demonstrates effectiveness in Phase I trial - Clinical Trials Arena

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in ... - Yahoo Finance

Tharimmune (NASDAQ: THAR) up 46% one day, down 68% the next - Surprise! - Dhaka Tribune

THARに似た銘柄